Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Updates from the LocoMMotion study

Hermann Einsele • 11 Jun 2022
EHA 2022
Multiple Myeloma Antibodies CAR-T
LOCOMMOTION

In this video, Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, shares some updates on the LocoMMotion study (NCT04035226). Prof. Einsele first discusses the overall survival (OS) and progression-free survival (PFS) observed, which further highlight the limited success of current treatment approaches and the importance of further investigating novel immunotherapies such as CAR-T therapy and bispecific antibodies in patients with relapsed/refractory (R/R) myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Hermann Einsele

2:44
Moving CAR-T into earlier lines of therapy in multiple myeloma
Hermann Einsele • 17 Feb 2024
0:45
CAR T-cell therapy in lenalidomide-refractory multiple myeloma
Hermann Einsele • 17 Feb 2024
1:19
Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myeloma
Hermann Einsele • 26 Jun 2023
8:16
Results from CARTITUDE-4: cilta-cel for lenalidomide-refractory multiple myeloma
Hermann Einsele • 26 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals